BUDGET IMPACT ANALYSIS OF REGORAFENIB IN THE THIRD-LINE TREATMENT OF PATIENTS WITH METASTATIC COLORECTAL CANCER

被引：0
|
作者：
Zhu, S. [1 ]
Liu, J. [1 ]
Sun, W. [2 ]
Xuan, J. [3 ]
机构：
[1] Shanghai Centennial Sci Co Ltd, Shanghai, Peoples R China
[2] Bayer Healthcare Co Ltd, Beijing, Peoples R China
[3] Sun Yat sen Univ, Guangzhou, Guangdong, Peoples R China
来源：
VALUE IN HEALTH | 2018年 / 21卷
关键词：
D O I：
10.1016/j.jval.2018.07.087
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN18
引用
收藏
页码：S12 / S12
页数：1
相关论文
共 50 条
  • [1] BUDGET IMPACT ANALYSIS OF REGORAFENIB IN THE TREATMENT OF THIRD-LINE METASTATIC COLORECTAL CANCER IN THE PERSPECTIVE OF THE BRAZILIAN SUPPLEMENTARY HEALTHCARE SYSTEM (SHS)
    Bergamelli Ramos, N.
    Palhares, R.
    Cruz, A. T.
    Fanti, L.
    Lemmer, T.
    [J]. VALUE IN HEALTH, 2019, 22 : S77 - S78
  • [2] Regorafenib in the third-line treatment of metastatic colorectal cancer: a retrospective study of 27 cases
    Boudinar, F.
    Larbaoui, B.
    [J]. ANNALS OF ONCOLOGY, 2019, 30
  • [3] A budget impact model of third-line or later trifluridine/tipiracil treatment of metastatic colorectal cancer.
    Ferrufino, Cheryl
    Wiseman, Fred
    Wert, Tim D.
    Barghout, Victoria
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [4] Regorafenib or rechallenge chemotherapy: which is more effective in the third-line treatment of metastatic colorectal cancer?
    Osman Köstek
    Muhammet Bekir Hacıoğlu
    Abdullah Sakin
    Tarık Demir
    Murat Sarı
    Ozlem Ozkul
    Murat Araz
    Aysun Fatma Doğan
    Nazım Can Demircan
    Sernaz Uzunoğlu
    İrfan Çiçin
    Bülent Erdoğan
    [J]. Cancer Chemotherapy and Pharmacology, 2019, 83 : 115 - 122
  • [5] Third-line treatment for metastatic colorectal cancer: anlotinib is superior to chemotherapy and similar to fruquintinib or regorafenib
    Cheng, Y.
    Du, F. C.
    Fang, F. Q.
    Duan, Z. J.
    Lei, W.
    Shi, K. G.
    [J]. NEOPLASMA, 2020, 67 (06) : 1384 - 1390
  • [6] Regorafenib Plus for third-line treatment in metastatic colorectal cancer: A real-world study
    Yisilamu, Patiguli
    Yao, Jiannan
    Ge, Yang
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [7] Regorafenib or rechallenge chemotherapy: which is more effective in the third-line treatment of metastatic colorectal cancer?
    Kostek, Osman
    Hacioglu, Muhammet Bekir
    Sakin, Abdullah
    Demir, Tarik
    Sari, Murat
    Ozkul, Ozlem
    Araz, Murat
    Dogan, Aysun Fatma
    Demircan, Nazim Can
    Uzunoglu, Sernaz
    Cicin, Irfan
    Erdogan, Buelent
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2019, 83 (01) : 115 - 122
  • [8] Treatment Outcomes of Metastatic Colorectal Cancer Patients Treated with Regorafenib as Third-Line Setting-A Multicenter Study
    Sahin, Suleyman
    Hacioglu, Muhammet Bekir
    [J]. ISTANBUL MEDICAL JOURNAL, 2019, 20 (02): : 82 - 87
  • [9] Metastatic Colorectal Cancer: Strategies for Third-Line Treatment
    Marshall, John L.
    [J]. CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (01) : 7 - 15
  • [10] Regorafenib therapy as a third-line treatment for metastatic colorectal cancer: A single center long term experience
    Ozkan, Merve
    Oflazoglu, Utku
    Yildiz, Yasar
    Guc, Zeynep G.
    Salman, Tarik
    Unal, Sinan
    Kucukzeybek, Yuksel
    Alacacioglu, Ahmet
    [J]. MEDICINE, 2023, 102 (50) : E36435
12345